Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Preiss

Showing results (151-160 of 160) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 160 results.
European Heart Journal|March 25, 2015
The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trialsDavid Preiss, Ross T Campbell, Heather M Murray, et al.
Nature|February 14, 2020
Publisher Correction: GDF15 mediates the effects of metformin on body weight and energy balanceAnthony P Coll, Michael Chen, Pranali Taskar, et al.
Lancet (London, England)|February 20, 2010
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsNaveed Sattar, David Preiss, Heather M Murray, et al.
The New England Journal of Medicine|October 25, 2024
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease, William G Herrington, Natalie Staplin, et al.
The New England Journal of Medicine|November 4, 2022
Empagliflozin in Patients with Chronic Kidney Disease, William G Herrington, Natalie Staplin, et al.
European Heart Journal Open|October 16, 2023
Intima-media thickness at the near or far wall of the common carotid artery in cardiovascular risk assessmentLisa Seekircher, Lena Tschiderer, Lars Lind, et al.
Circulation|June 18, 2020
Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 PatientsPeter Willeit, Lena Tschiderer, Elias Allara, et al.
The Lancet. Diabetes & Endocrinology|December 3, 2016
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation studyAmand F Schmidt, Daniel I Swerdlow, Michael V Holmes, et al.
Lancet (London, England)|September 29, 2014
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trialsDaniel I Swerdlow, David Preiss, Karoline B Kuchenbaecker, et al.
BMC Cardiovascular Disorders|October 31, 2019
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9Amand F Schmidt, Michael V Holmes, David Preiss, et al.
Pageof 16

Showing results (151-160 of 160) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 160 results.
European Heart Journal|March 25, 2015
The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trialsDavid Preiss, Ross T Campbell, Heather M Murray, et al.
Nature|February 14, 2020
Publisher Correction: GDF15 mediates the effects of metformin on body weight and energy balanceAnthony P Coll, Michael Chen, Pranali Taskar, et al.
Lancet (London, England)|February 20, 2010
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsNaveed Sattar, David Preiss, Heather M Murray, et al.
The New England Journal of Medicine|October 25, 2024
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease, William G Herrington, Natalie Staplin, et al.
The New England Journal of Medicine|November 4, 2022
Empagliflozin in Patients with Chronic Kidney Disease, William G Herrington, Natalie Staplin, et al.
European Heart Journal Open|October 16, 2023
Intima-media thickness at the near or far wall of the common carotid artery in cardiovascular risk assessmentLisa Seekircher, Lena Tschiderer, Lars Lind, et al.
Circulation|June 18, 2020
Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 PatientsPeter Willeit, Lena Tschiderer, Elias Allara, et al.
The Lancet. Diabetes & Endocrinology|December 3, 2016
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation studyAmand F Schmidt, Daniel I Swerdlow, Michael V Holmes, et al.
Lancet (London, England)|September 29, 2014
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trialsDaniel I Swerdlow, David Preiss, Karoline B Kuchenbaecker, et al.
BMC Cardiovascular Disorders|October 31, 2019
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9Amand F Schmidt, Michael V Holmes, David Preiss, et al.
Pageof 16